Get the Stockscreener App
11.67
10.30%
1.09
After Hours:
11.67
Vor Biopharma Inc stock is traded at $11.67, with a volume of 1.40M.
It is up +10.30% in the last 24 hours and up +42.67% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
See More
Previous Close:
$10.58
Open:
$10.7
24h Volume:
1.40M
Relative Volume:
0.87
Market Cap:
$255.70M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-7.1159
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
-6.86%
1M Performance:
+42.67%
6M Performance:
-69.45%
1Y Performance:
-66.47%
1-Day Range:
$10.29
$11.75
1-Week Range:
$10.29
$13.60
52-Week Range:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
500 BOYLSTON STREET, BOSTON
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
11.67 | 231.81M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Initiated | TD Cowen | Buy |
| Dec-09-25 | Initiated | JP Morgan | Overweight |
| Nov-25-25 | Resumed | Wedbush | Neutral |
| Oct-15-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-25 | Upgrade | Stifel | Hold → Buy |
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
What drives Vor Biopharma Inc stock priceInstitutional Buying Trends & Low Entry Cost Trading - earlytimes.in
Ariose Capital Management Ltd Invests $5.37 Million in Vor Biopharma Inc. $VOR - MarketBeat
Vor Biopharma Inc Stock Analysis and ForecastSell Signals and Alerts & Free High Yield Growth Strategies - earlytimes.in
Aug Macro: Will Vor Biopharma Inc stock outperform international peersFed Meeting & Verified Momentum Stock Watchlist - moha.gov.vn
Vor Biopharma CDO Departs, Transition Support Planned - TipRanks
Vor Biopharma Target of Unusually High Options Trading (NASDAQ:VOR) - MarketBeat
Portfolio Update: How Vor Biopharma Inc. stock benefits from global expansionTrade Risk Report & Fast Entry and Exit Trade Plans - moha.gov.vn
Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors - ts2.tech
Gap Down: Is Vor Biopharma Inc stock positioned well for digital economyJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - moha.gov.vn
Vor Biopharma (VOR) Stock Analysis Report | Financials & Insights - Benzinga
Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Moving Averages: How strong is Celsius Holdings Inc stock balance sheet2025 Short Interest & Community Verified Swing Trade Signals - moha.gov.vn
Vor Biopharma Stock (+7.4%): New Board Signals Institutional Backing - Trefis
Vor Biopharma Inc. (NASDAQ:VOR) Sees Large Growth in Short Interest - MarketBeat
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors - The Globe and Mail
Vor Biopharma adds two investment partners to board of directors By Investing.com - Investing.com Nigeria
Vor Biopharma Inc Announces Board Appointments - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to NASDAQ Biotechnology Index - marketscreener.com
How Vor Biopharma Inc. stock benefits from global expansionIndex Update & Risk Controlled Swing Alerts - Улправда
VOR: JP Morgan Lowers Price Target While Maintaining Overweight Rating | VOR Stock News - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
Why Vor Biopharma Inc. stock appeals to dividend seekersJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - ulpravda.ru
Vor Biopharma Signs Multiple Financing Agreements - TradingView — Track All Markets
Vor Biopharma (VOR) secures $150M private placement and adds two directors - Stock Titan
Technical Analysis: Will Vor Biopharma Inc. stock reach all time highs in 2025Earnings Performance Report & Accurate Technical Buy Alerts - Улправда
Vor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpoint - MSN
Vor Biopharma: Initiating Hold Rating On Durable Telitacicept MG Study Data - Seeking Alpha
Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential By Investing.com - Investing.com South Africa
VOR: TD Cowen Initiates Coverage with a 'Buy' Rating | VOR Stock News - GuruFocus
Vor Biopharma (NASDAQ:VOR) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Stocks to watch: Vor Biopharma sees RS rating jump to 89 - MSN
TD Cowen Initiates Vor Biopharma at Buy - marketscreener.com
Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential - Investing.com Australia
TD Cowen Starts Vor Biopharma, Inc. (VOR) at Buy - StreetInsider
Vor Biopharma’s Surge: New Opportunities? - StocksToTrade
HC Wainwright & Co. Maintains Vor Biopharma (VOR) Buy Recommendation - MSN
Aug Chart Watch: Why Vor Biopharma Inc stock remains resilientPortfolio Performance Report & Free Technical Confirmation Trade Alerts - moha.gov.vn
Vor Biopharma Launches $150 Million Private Placement; Shares Rise - marketscreener.com
Vor Bio announces $150 million private placement - marketscreener.com
Vor Bio announces $150M private placement - MSN
Vor Bio Announces $150 Million Private Placement - Yahoo Finance
VOR shares rally over 40% in pre-market trade after JPMorgan initiates bullish coverage - MSN
Manufacturing Stocks To Keep An Eye OnDecember 9th - MarketBeat
Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed? - Yahoo Finance
Vor Biopharma approves stock option repricing plan - MSN
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vor Biopharma Inc Stock (VOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 28 '25 |
Sale |
27.42 |
124,311 |
3,408,230 |
1,055,749 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 30 '25 |
Sale |
25.12 |
24,579 |
617,424 |
779,652 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 27 '25 |
Sale |
28.12 |
90,941 |
2,557,261 |
1,180,060 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 23 '25 |
Sale |
28.01 |
76,880 |
2,153,409 |
1,324,346 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 24 '25 |
Sale |
28.01 |
53,345 |
1,494,193 |
1,271,001 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 20 '25 |
Sale |
29.67 |
92,023 |
2,730,483 |
0 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 21 '25 |
Sale |
28.11 |
25,027 |
703,509 |
1,401,226 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 17 '25 |
Sale |
30.25 |
25,717 |
777,987 |
1,178,725 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 20 '25 |
Sale |
30.05 |
11,616 |
349,101 |
1,167,109 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 21 '25 |
Sale |
30.07 |
200 |
6,015 |
1,166,909 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):